Managing the challenges of invasive fungal infections

International Journal of Antimicrobial Agents

Volumn 27, Issue SUPPL. 1, 2006, Pages 1-2

  Herbrecht, Raoul ^a  

^a HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ECHINOCANDIN; PYRROLE; PYRROLE DERIVATIVE;

ASPERGILLOSIS; EDITORIAL; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE DEFICIENCY; MUCORMYCOSIS; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; DRUG RESISTANCE, MICROBIAL; HUMANS; INCIDENCE; MYCOSES; RISK FACTORS;

EID: 33646824866     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.03.002     Document Type: Editorial

References (12)

1. Marr K.A., Carter R.A., Crippa F., Wald A., and Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34 (2002) 909-917
2. Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 33 (2001) 1692-1696
3. Gallagher J.C., Dodds Ashley E.S., and Drew R.H. Antifungal pharmacotherapy for invasive mould infections. Expert Opin Pharmacother 4 (2003) 147-164
4. Marques S.A., Robles A.M., Tortorano A.M., et al. Mycoses associated with AIDS in the Third World. Med Mycol 38 Suppl 1 (2000) 269-279
5. Wald A., Leisenring W., van Burik J.A., and Bowden R.A. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 175 (1997) 1459-1466
6. Viscoli C., Girmenia C., Marinus A., et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 28 (1999) 1071-1079
7. Marty F.M., Cosimi L.A., and Baden L.R. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 350 (2004) 950-952
8. Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemother 49 Suppl 1 (2002) 31-36
9. Wingard J.R., Kubilis P., Lee L., et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 29 (1999) 1402-1407
10. Denning D.W. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 23 (1996) 608-615
11. Patterson T.F., Kirkpatrick W.R., White M., et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 79 (2000) 250-260
12. Chandrasekar P.H., and Ito J.I. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 40 Suppl 6 (2005) S392-S400